Statins: Another class of antihypertensive agents?

Journal of Human Hypertension

Volumn 20, Issue 5, 2006, Pages 320-335

  Milionis, H J ^a   Liberopoulos, E N ^b   Achimastos, A ^c   Elisaf, M S ^a   Mikhailidis, D P ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Blood pressure; Dyslipidaemia; Pleiotropic effects; Statins; Vascular disease

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; BEZAFIBRATE; CAPTOPRIL; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN 1; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; MEVINOLIN; PERINDOPRIL; PITAVASTATIN; PRAVASTATIN; PROBUCOL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG CLASSIFICATION; DRUG RESPONSE; DYSLIPIDEMIA; GENETIC LINKAGE; GENETIC RISK; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FUNCTION; MONOTHERAPY; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR RESISTANCE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 33646037997     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002001     Document Type: Review

References (146)

1. Grundy SM, Pasternak R, Greenland P, Smith Jr S, Fuster V. AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 1999; 34: 1348-1359.
2. Muntner P, He J, Roccella EJ, Whelton PK. The impact of JNC-VI guidelines on treatment recommendations in the US population. Hypertension 2002; 39: 897-902.
3. Laurenzi M, Mancini M, Menotti A, Stamler J, Stamler R, Trevisan M et al. Multiple risk factors in hypertension: Results from the Gubbio study. J Hypertens Suppl 1990; 8: S7-S12.
4. Goode GK, Miller JP, Heagerty AM. Hyperlipidaemia, hypertension, and coronary heart disease. Lancet 1995; 345: 362-364.
5. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology 2004; 55: 589-612.
6. Elisaf M, Mikhailidis DP. Statins and renal function. Angiology 2002; 53: 493-502.
7. Pedrinelli R, Esposti ED, Dell'Omo G. LDL cholesterol and global risk stratification in referred hypertensive patients. Atherosclerosis 2005; 180: 137-143.
8. Halperin RO, Sesso HD, Ma J, Buring JE, Stampfer MJ, Gaziano JM. Dyslipidemia and the risk of incident hypertension in men. Hypertension 2006; 47: 45-50.
9. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428.
10. Liberopoulos EN, Elisaf MS. Diagnosis of the metabolic syndrome: Which definition should we use? Hellenic J Cardiol 2005; 46: 258-262.
11. Gazi I, Liberopoulos E, Mikhailidis DP, Elisaf M. Metabolic syndrome: clinical features leading to therapeutic strategies. Vasc Dis Prevent 2004; 1: 243-253.
12. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
13. Fagot-Campagna A, Balkau B, Simon D, Warnet JM, Claude JR, Ducimetiere P et al. High free fatty acid concentration: An independent risk factor for hypertension in the Paris Prospective Study. Int J Epidemiol 1998; 27: 808-813.
14. Bulow J, Madsen J, Hojgaard L. Reversibility of the effects on local circulation of high lipid concentrations in blood. Scand J Clin Lab Invest 1990; 50: 291-296.
15. Egan BM, Hennes MM, Stepniakowski KT, O'Shaughnessy IM, Kissebah AH, Goodfriend TL et al. Obesity hypertension is related more to insulin's fatty acid than glucose action. Hypertension 1996; 27: 723-728.
16. Stojiljkovic MP, Zhang D, Lopes HF, Lee CG, Goodfriend TL, Egan BM. Hemodynamic effects of lipids in humans. Am J Physiol 2001; 280: R1674-R1679.
17. Misra A, Cherukupalli R, Reddy KS, Mohan A, Bajaj JS. Hyperinsulinemia and dyslipidemia in non-obese, normotensive offspring of hypertensive parents in northern India. Blood Pressure 1998; 7: 286-290.
18. Williams RR, Hunt SC, Hopkins PN, Stults BM, Wu LL, Hasstedt SJ et al. Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome resent in approximately 12% of patients with essential hypertension. JAMA 1988; 259: 3579-3586.
19. Lopes HF, Stojiljkovic MP, Zhang D, Goodfriend TL, Egan BM. The pressor response to acute hyperlipidemia is enhanced in lean normotensive offspring of hypertensive parents. Am J Hypertens 2001; 14: 1032-1037.
20. Sung BH, Izzo JL, Wilson MF. Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol. Am J Hypertens 1997; 10: 592-599.
21. Minami M, Atarashi K, Ishiyama A, Hirata Y, Goto A, Omata M. Effects of cholesterol-lowering therapy on pressor hyperreactivity to stress in hypercholesterolemic patients. Hypertens Res 2003; 26: 273-280.
22. Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K. The association of borderline hypertension with target organ changes and higher coronary risk. Tecumseh Blood Pressure study. JAMA 1990; 264: 354-358.
23. Poulter NR, Zographos D, Mattin R, Sever PS, Thom SM. Concomitant risk factors in hypertensives: A survey of risk factors for cardiovascular disease amongst hypertensives in English general practices. Blood Pressure 1996; 5: 209-215.
24. Borghi C, Veronesi M. Hypercholesterolemia as cardiovascular risk in hypertensive patients. Therapeutic implications: Efficiency of statins. Recenti Prog Med 2003; 94: 421-426.
25. Matsubara K, Yamamoto Y, Sonoyama K, Igawa G, Furuse M, Yatsuhashi T et al. Current status of lipid management of hypertensive patients. Hypertens Res 2003; 26: 699-704.
26. Bottger A, van Lith HA, Kren V, Krenova D, Bila V, Vorlicek J et al. Quantitative trait loci influencing cholesterol and phospholipid phenotypes map to chromosomes that contain genes regulating blood pressure in the spontaneously hypertensive rat. J Clin Invest 1996; 98: 856-862.
27. Grundy SM, Chait A, Brunzell JD. Familial combined hyperlipidemia workshop. Arteriosclerosis 1987; 7: 203-207.
28. Allayee H, de Bruin TW, Michelle Dominguez K, Cheng LS, Ipp E, Cantor RM et al. Genome scan for blood pressure in Dutch dyslipidemic families reveals linkage to a locus on chromosome 4p. Hypertension 2001; 38: 773-778.
29. Wierzbicki AS. Lipid lowering: Another method of reducing blood pressure? J Hum Hypertens 2002; 16: 753-760.
30. Ferrari P, Weidmann P, Shaw S, Giachino D, Riesen W, Allemann Y et al. Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parent. Am J Med 1991; 91: 589-596.
31. Pereira AC, Sposito AC, Mota GF, Cunha RS, Herkenhoff FL, Mill JG et al. Endothelial nitric oxide synthase gene variant modulates the relationship between serum cholesterol levels and blood pressure in the general population: New evidence for a direct effect of lipids in arterial blood pressure. Atherosclerosis 2006; 184: 193-200.
32. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
33. Rizos E, Mikhailidis DP. Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention? Cardiovasc Res 2001; 52: 199-207.
34. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
35. Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP, Wierzbicki AS, Elisaf MS. A review of the lipid-related effects of fluvastatin. Curr Med Res Opin 2005; 21: 231-243.
36. Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997; 30: 968-974.
37. Regrigny O, Atkinson J, Capdeville-Atkinson C, Liminana P, Chillon JM. Effect of lovastatin on cerebral circulation in spontaneously hypertensive rats. Hypertension 2000; 35: 1105-1110.
38. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 1998; 31: 225-231.
39. Gross V, Schneider W, Schunck WH, Mervaala E, Luft FC. Chronic effects of lovastatin and bezafibrate on cortical and medullary hemodynamics in deoxycorticosterone acetate-salt hypertensive mice. J Am Soc Nephrol 1999; 10: 1430-1439.
40. Yamashita T, Kawashima S, Miwa Y, Ozaki M, Namiki M, Hirase T et al. A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats. J Hypertens 2002; 20: 2465-2473.
41. Kawashima S, Yamashita T, Miwa Y, Ozaki M, Namiki M, Hirase T et al. HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke 2003; 34: 157-163.
42. Kishi T, Hirooka Y, Mukai Y, Shimokawa H, Takeshita A. Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. J Hypertens 2003; 21: 379-386.
43. Susic D, Varagic J, Ahn J, Slama M, Frohlich ED. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 2003; 42: 1091-1097.
44. Ge CJ, Hu SJ, Wu YS, Chen NY. Effects of atorvastatin on vascular remodeling in spontaneously hypertensive rats. J Zhejiang Univ Sci 2003; 4: 612-615.
45. Borghi C, Veronesi M, Prandin MG, Dormi A, Ambrosioni E. Statins and blood pressure regulation. Curr Hypertens Rep 2001; 3: 281-288.
46. Borghi C, Dormi A, Veronesi M, Immordino V, Ambrosioni E. Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension. J Clin Hypertens (Greenwich) 2002; 4: 277-285.
47. Pelat T, Balligand JL. Statins and hypertension. Semin Vasc Med 2004; 4: 367-375.
48. Blanco-Colio LM, Osende JI, Martin-Ventura JL, Tunon J, Egido J. Statins in hypertensive patients: Potential explanations for the ASCOT-LLA study results. Drugs 2004; 64(Suppl 2): 61-67.
49. Jarai Z, Kapocsi J, Farsang C, Detki K, Pados G, Sebestyen Z et al. Effect of fluvastatin on serum lipid levels in essential hypertension. Orv Hetil 1996; 137: 1857-1859.
50. Abetel G, Poget PN, Bonnabry JP. Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin): A pilot study. Schweiz Med Wochenschr 1998; 128: 272-277.
51. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 36: 1281-1291.
52. Morgan T, Anderson A, McDonald P, Hopper J, Macaskill G. Simvastatin in the treatment of hypercholesterolaemia in patients with essential hypertension. J Hypertens Suppl 1990; 8: S25-S30.
53. Tonolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P et al. Additive effects of simvastatin beyond its effect on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000; 30: 980-987.
54. Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39: 1020-1025.
55. Prasad GVR, Ahmed A, Nash MM, Zaltzman JS. Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients. Kidney Int 2003; 63: 360-364.
56. Terzoli L, Mircoli L, Raco R, Ferrari AU. Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors. J Cardiovasc Pharmacol 2005; 46: 310-315.
57. Kanbay M, Yildirir A, Bozbas H, Ulus T, Bilgi M, Muderrisoglu H et al. Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients. Renal Failure 2005; 27: 297-303.
58. Magen E, Viskoper R, Mishal J, Priluk R, Berezovsky A, Laszt A et al. Resistant arterial hypertension and hyperlipidemia: Atorvastatin, not vitamin C, for blood pressure control. Isr Med Assoc J 2004; 6: 742-746.
59. Borghi C, Dormi A, Veronesi M, Sangiorgi Z, Gaddi A, Brisighella Heart Study Working Party. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J 2004; 148: 285-292.
60. Sartor G, Katzman P, Eizyk E, Kalen J, Nilsson A, Ugander L et al. Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus. Int J Clin Pharmacol Ther 1995; 33: 3-6.
61. Antonicelli R, Onorato G, Pagelli P, Pierazzoli L, Paciaroni E. Simvastatin in the treatment of hypercholesterolemia in elderly patients. Clin Ther 1990; 12: 165-171.
62. Kool M, Lustermans F, Kragten H, Struijker Boudier H, Hoeks A, Reneman R et al. Does lowering of cholesterol levels influence functional properties of large arteries? Eur J Clin Pharmacol 1995; 48: 217-223.
63. D'Agostino RB, Kannel WB, Stepanians MN, D'Agostino LC. Efficacy and tolerability of lovastatin in hypercholesterolemia in patients with systemic hypertension. Am J Cardiol 1993; 71: 82-87.
64. Ichihara A, Hayashi M, Koura Y, Tada Y, Kaneshiro Y, Saruta T. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens 2005; 19: 103-109.
65. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
66. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23: 729-736.
67. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-1457.
68. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135.
69. Endres M, Laufs U, Huang ZH, Nakamura T, Huang P, Moskowitz MA et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95: 8880-8885.
70. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103: 1245-1249.
71. Langille DB, Joffres MR, MacPherson KM, Andreou P, Kirkland SA, MacLean DR. Prevalence of risk factors for cardiovascular disease in Canadians 55-74 years of age: Results from the Canadian Heart Health Surveys, 1986-1992. Can Med Assoc J 1999; 161: S3-S9.
72. Asmar R. Effect of antihypertensive agents on arterial stiffness as evaluated by pulse wave velocity: Clinical implications. Am J Cardiovasc Drugs 2001; 1: 387-397.
73. Meaume S, Rudnichi A, Lynch A, Bussy C, Sebban C, Benetos A et al. Aortic pulse wave velocity as a marker of cardiovascular disease in subjects over 70 years old. J Hypertens 2001; 19: 871-877.
74. Kontopoulos AG, Athyros VG, Pehlivanidis AN, Demitriadis DS, Papageorgiou AA, Boudoulas H. Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. Curr Med Res Opin 2003; 19: 22-27.
75. Raison J, Rudnichi A, Safar ME. Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: A preliminary study. J Hum Hypertens 2002; 16: 705-710.
76. Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 2003; 93: E98-e103.
77. Liberopoulos EN, Daskalopoulou SD, Mikhailidis DP. Early statin therapy in patients with acute coronary syndromes. Hellenic J Cardiol 2005; 46: 5-8.
78. Schiffrin EL. Endothelin; potential role in hypertension and vascular hypertrophy. Hypertension 1995; 25: 1135-1143.
79. Donckier JE, Massart PE, Hodeige D, Van Mechelen H, Clozel JP, Laloux O et al. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition. Circulation 1997; 96: 1250-1256.
80. Barton M, Kiowski W. The therapeutic potential of endothelin receptor antagonists in cardiovascular disease. Curr Hypertens Rep 2001; 3; 322-330.
81. Nakov R, Pfarr E, Eberle S, HEAT investigators. Darusentan: An effective endothelin A receptor antagonist for treatment of hypertension. Am J Hypertens 2002; 15: 583-589.
82. Haynes WG, Hand MF, Johnstone HA, Padfield PL, Webb DJ. Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1. J Clin Invest 1994; 94: 1359-1364.
83. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C et al. Effects of the 3-hydroxy-3-methylgluraryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711-2719.
84. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes - The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99: 3227-3233.
85. Gottsater A, Anwaar I, Lind P, Mattiasson I, Lindgarde F. Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin. Blood Coagul Fibrinolysis 1999; 10: 133-140.
86. Ferrario CM, Smith R, Levy P, Strawn W. The hypertension-lipid connection: Insights into the relation between angiotensin II and cholesterol in atherogenesis. Am J Med Sci 2002; 323: 17-24.
87. Straznicky NE, Howes LG, Lam W, Louis WJ. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol 1995; 75: 582-586.
88. Ide H, Fujiya S, Aanuma Y, Agishi Y. Effects of simvastatin, an HMG CoA reductase inhibitor, on plasma lipids and steroid hormones. Clin Ther 1990; 12: 410-420.
89. 1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-2134.
90. Soma M, Manku MS, Horrobin DF. The effects of hydrogenated coconut oil, safflower oil, and evening primrose oil on development of hypertension and sodium handling in spontaneously hypertensive rats. Can J Physiol Pharmacol 1985; 63: 325-330.
91. Rubattu S, Volpe M, Enea I, Russo R, Romano M, Trimarco B. Influence of hypercholesterolemia on adrenal steroid metabolism and electrolyte balance in spontaneously hypertensive rats. Endocrinology 1993; 133: 2015-2021.
92. Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J 2004; 148: 635-640.
93. Moosmang S, Schulla V, Welling A, Feil R, Feil S, Wegener JW et al. Dominant role of smooth muscle L-type calcium channel Cav1.2 for blood pressure regulation. EMBO J 2003; 22: 6027-6034.
94. Cox RH, Tulenko TN. Altered contractile and ion channel function in rabbit portal vein with dietary atherosclerosis. Am J Physiol Heart Circ Physiol 1995; 268: H2522-H2530.
95. Tulenko TN, Chen M, Mason PE, Mason RP. Physical effects of cholesterol on arterial smooth muscle membranes: Evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis. J Lipid Res 1998; 39: 947-956.
96. Levitan I, Christian AE, Tulenko TN, Rothblat GH. Membrane cholesterol content modulates activation of volume-regulated anion current in bovine endothelial cells. J Gen Physiol 2000; 115: 405-416.
97. 2+ responses in rat A10 vascular smooth muscle cells. Circ Res 1994; 74: 173-181.
98. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
99. Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993; 153: 578-581.
100. Samuelsson OG, Wilhelmsen LW, Pennert KM, Wedel H, Berglund GL. The J-shaped relationship between coronary heart disease and achieved blood pressure level in treated hypertension: Further analyses of 12 years of follow-up of treated hypertensives in the Primary Prevention Trial in Gothenburg, Sweden. J Hypertens 1990; 8: 547-555.
101. Manttari M, Tenkanen L, Manninen V, Alikoski T, Frick MH. Antihypertensive therapy in dyslipidemic men. Effects on coronary heart disease incidence and total mortality. Hypertension 1995; 25: 47-52.
102. Athyros VG, Mikhailidis DP, Papageorgiou AA, Bouloukos VI, Pehlivanidis AN, Symeonidis AN et al. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004; 18: 781-788.
103. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998-3007.
104. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004; 291: 1071-1080.
105. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
106. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, et al., for the Treating to New Targets (TNT) investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
107. Liberopoulos EN, Athyros VG, Elisaf MS, Mikhailidis DP. Targets for low-density lipoprotein cholesterol levels in patients with stable coronary heart disease: Where are we now after the 'treating to new targets' (TNT) trial? Hellenic J Cardiol 2005; 46: 161-164.
108. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil AW, Livingstone SJ, et al., on behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre, randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
109. Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I et al. for the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. JAMA 2005; 294: 2437-2445.
110. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as requested versus atenolol adding bendroflumethiazide as requested, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
111. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779-785.
112. Obarzanek E, Proschan MA, Vollmer WM, Moore TJ, Sacks FM, Appel LJ et al. Individual blood pressure responses to changes in salt intake: results from the DASH-Sodium trial. Hypertension 2003; 42: 459-467.
113. Liberopoulos EN, Mikhailidis DP, Elisaf MS. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev 2005; 6: 283-296.
114. Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: An overview of lifestyle and pharmacological measures. Curr Drug Targets 2006; 7, in press.
115. Tsouli SG, Liberopoulos EN, Kiortsis DN, Mikhailidis DP, Elisaf MS. Combined treatment with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: A review of the current evidence. J Cardiovasc Pharmacol Ther 2006; 11, in press.
116. Ganotakis ES, Papadakis JA, Vrentzos GE, Mikhailidis DP. The effects of antihypertensive therapy on haemostatic parameters. Curr Pharm Design 2003; 9: 2445-2464.
117. Papadakis JA, Ganotakis ES, Jagroop IA, Mikhailidis DP, Winder AF. Effect of hypertension, and its treatment, on lipid, lipoprotein (a), fibrinogen and bilirubin levels in patients referred for dyslipidaemia. Am J Hypertens 1999; 12: 673-681.
118. Kowala MC, Valentine M, Recce R, Beyer S, Goller N, Durham S et al. Enhanced reduction of atherosclerosis in hamsters treated with pravastatin and captopril: ACE in atheromas provides cellular targets for captopril. J Cardiovasc Pharmacol 1998; 32: 29-38.
119. Ikeda T, Sakurai J, Nakayama D, Takahashi Y, Matsuo K, Shibuya Y et al. Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs. Am J Hypertens 2004; 17: 502-506.
120. Nazzaro P, Manzari M, Merlo M, Triggiani R, Scarano A, Ciancio L et al. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999; 33: 719-725.
121. Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JA. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999; 83: 1497-1499.
122. Oubina MP, de las Heras N, Cediel E, Sanz-Rosa D, Aragoncill P, Diaz C et al. Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits. Clin Sci 2003; 105: 655-662.
123. Leibovitz E, Beniashvili M, Zimlichman R, Freiman A, Shargorodsky M, Gavish D. Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am J Hypertens 2003; 16: 715-718.
124. Horiuchi M, Cui TX, Li Z, Li JM, Nakagami H, Iwai M. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 2003; 107: 106-112.
125. Su SF, Hsiao CL, Chu CW, Lee BC, Lee TM. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Am J Cardiol 2000; 86: 514-518.
126. Anderssen SA, Hjelstuen AK, Hjermann I, Bjerkan K, Holme I. Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis 2005; 178: 387-397.
127. Simko F, Matuskova J, Luptak I, Krajcirovicova K, Kucharska J, Gvozdjakova A et al. Effect of simvastatin on remodelling of the left ventricle and aorta in L-NAME-induced hypertension. Life Sci 2004; 74: 1211-1224.
128. Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on renal function. Am J Kidney Dis 2005; 45: 2-14.
129. Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI et al. GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004; 43: 589-599.
130. Youssef F, Gupta P, Seifalian AM, Myint F, Mikhailidis DP, Hamilton G. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 2004; 55: 53-62.
131. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
132. Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP, GREACE Study Collaborative Group. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 2003; 19: 615-617.
133. Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis DP. Uric acid levels and vascular disease. Curr Med Res Opin 2004; 20: 951-954.
134. Youssef F, Seifalian AM, Jagroop A, Myint F, Baker D, Mikhailidis DP et al. The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vasc Endovasc Surg 2002; 23: 358-364.
135. Afzali B, Goldsmith DJA. Beneficial effects of statins on the kidney. J Clin Pathol 2004; 57: 673-674.
136. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-734.
137. Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. The effect of cholesterol-lowering treatment on renal function. Am J Kidney Dis 2006; in press.
138. Milionis HJ, Liberopoulos E, Goudevenos J, Bairaktari ET, Seferiadis K, Elisaf MS. Risk factors for first-ever ischemic non-embolic stroke in elderly individuals. Int J Cardiol 2005; 99: 269-275.
139. Green R, Kwok S, Durrington PN. Preventing cardiovascular disease in hypertension: Effects of lowering blood pressure and cholesterol. QJM 2002; 95: 821-826.
140. Champman N. New evidence on hypertension and hyperlipidaemia. Heart 2004; 90(Suppl iv): Iv14-iv17.
141. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
142. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
143. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
144. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
145. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
146. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM et al. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002; 360: 1623-1630.